跳转至内容
Merck

1095506

USP

(S)-3-(3,4-二羟基苯基)-2-肼基-2-甲基丙酸 一水合物

United States Pharmacopeia (USP) Reference Standard

别名:

(S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropionic acid monohydrate

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C10H14N2O4 · H2O
CAS号:
分子量:
244.24
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

carbidopa

製造商/商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

O.C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O

InChI

1S/C10H14N2O4.H2O/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H2/t10-;/m0./s1

InChI 密鑰

QTAOMKOIBXZKND-PPHPATTJSA-N

基因資訊

human ... DDC(1644)

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Carbidopa USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Carbidopa and Levodopa Extended-Release Tablets
  • Carbidopa and Levodopa Orally Disintegrating Tablets
  • Carbidopa and Levodopa Tablets

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral - Eye Irrit. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Mohseni Mehran S M et al.
Journal of clinical and diagnostic research : JCDR, 7(6), 1004-1007 (2013-08-02)
According to many studies, sprouted fava beans are a rich source of levo-dihydroxy phenylalanine (L-dopa) the precursor of dopamine, and they are now being investigated for use in the management of Parkinson's disease. The addition of Carbidopa (C-dopa) can reduce
Q. Alan Xu, Timothy L. Madden
Analytical Methods for Therapeutic Drug Monitoring and Toxicology, 80-80 (2011)
Ina Schabram et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 34(44), 14769-14776 (2014-10-31)
Methylphenidate (MPH) inhibits the reuptake of dopamine and noradrenaline. PET studies with MPH challenge show increased competition at postsynaptic D2/3-receptors, thus indirectly revealing presynaptic dopamine release. We used [(18)F]fluorodopamine ([(18)F]FDOPA)-PET in conjunction with the inlet-outlet model (IOM) of Kumakura et
Fabrizio Stocchi et al.
Clinical neuropharmacology, 33(4), 198-203 (2010-04-24)
Parkinson disease is a progressive movement disorder caused by loss of dopaminergic neurons in the substantia nigra. Of unknown etiology, Parkinson disease is characterized by 4 cardinal symptoms: tremor at rest, bradykinesia, postural instability, and rigidity. The current criterion-standard drug
A Castro et al.
Neurologia (Barcelona, Spain), 20(4), 180-188 (2005-05-14)
Levodopa remains the mainstay treatment for Parkinson's disease (PD). Chronic treatment is associated with motor complications (MC) that marred the clinical benefit of levodopa. These problems and experimental data in cell cultures indicating a neurotoxic effect of levodopa have led

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门